NEW YORK, May 23 - Pyrosequencing on Wednesday took a step closer to entering the diagnostics market, announcing that it had received a patent for assessing cardiovascular conditions such as myocardial infarction and stroke.
“This is extraordinarily important – it establishes us as a player in diagnostics in the cardiovascular area,” Jerry Williamson, vice president of global diagnostics, told GenomeWeb.
The patent Pyrosequencing, an Uppsala, Sweden-based developer of SNP detection technology, received covers the company’s method for determining SNP patterns associated with cardiovascular disease as well as the use of SNP patterns in predicting patient responses to cardiovascular treatments.
The patent describes the use of genetic polymorphic patterns within the angiotensin converting enzyme gene, the angiotensin gene and the angiotensin II receptor type I gene. Pyrosequencing's patent also covers the use of polymorphic patterns in the ACE, AGT, and AT1 genes to predict patient response to cardiovascular therapeutics
Williamson said it was still too early to tell when this milestone would translate into a clinical product. However, he noted that Pyrosequencing was currently working to determine which of its assays it would want to develop into a clinical application. In addition to cardiovascular applications, the company is also interested in developing molecular diagnostics for cancer, metabolic disorders and other diseases.
Williamson said Pyrosequencing would like to work with pharmaceutical companies to help them to develop drugs and medical tests.